ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
Go back to ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 27.45 -0.09 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.54 | 52 Week High | $42.49 | |||
| Open | $27.78 | 52 Week Low | $16.64 | |||
| Day High | $28.06 | P/E | N/A | |||
| Day Low | $27.29 | EPS | $-0.42 | |||
| Volume | 1,307,767 | |||||
